165 results on '"Wong, Alyson W."'
Search Results
2. Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis
3. Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort
4. Characteristics and risk factors of interstitial pneumonia with autoimmune features
5. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis
6. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
7. A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies
8. Evaluating fatigue in patients recovering from COVID-19: validation of the fatigue severity scale and single item screening questions
9. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease
10. Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort
11. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
12. Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
13. Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response
14. Characteristics and risk factors of interstitial pneumonia with autoimmune features
15. Impact of antigen exposure on outcomes and treatment response in fibrotic hypersensitivity pneumonitis
16. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease
17. The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study.
18. Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease
19. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
20. A Learning Health System for Long Covid Care and Research in British Columbia
21. The Fatigue Severity Scale in Interstitial Lung Disease: An Energizing Endpoint
22. Fatigue presentation, severity, and related outcomes in a prospective cohort following post-COVID-19 hospitalization in British Columbia, Canada
23. Progression of fibrosing interstitial lung disease
24. Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort
25. Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease
26. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
27. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions
28. An Elastic Net Regression Model for Identifying Long COVID Patients Using Health Administrative Data: A Population-Based Study
29. Use of latent class analysis and patient reported outcome measures to identify distinct long COVID phenotypes: A longitudinal cohort study.
30. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement
31. Natural history of COVID-19 recovery: Changes in physiologic, radiologic and patient-reported outcomes 12 months after symptom onset
32. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
33. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
34. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry
35. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease
36. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis
37. The Genomic Classifier and Our Quest for Diagnostic Certainty in Interstitial Lung Disease
38. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry
39. Additional file 1 of A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies
40. Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease.
41. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Non-IPF Fibrotic Interstitial Lung Disease
42. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea
43. Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease.
44. Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study
45. Providing Patient-Centered Care in Interstitial Lung Disease
46. Update in Interstitial Lung Disease 2020
47. Pulmonary Apical Cap as a Potential Risk Factor for Pleuroparenchymal Fibroelastosis
48. Additional file 1 of Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease
49. Validation and minimum important difference of the UCSD shortness of breath questionnaire in fibrotic interstitial lung disease
50. Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.